Recent Advances in the Treatment and Management of Metastatic Breast Cancer: Expert Perspectives in an Evolving Treatment Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2021 to March 1, 2022


Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2020. The incidence in women in the United States is 1 in 8 (about 12 percent). About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors, have recently become available. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HER2- metastatic breast cancer.

With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose breast cancer and its corresponding stage, and provide the best evidenced-based treatment that is available for patients. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Therapy for advanced breast cancer is increasingly personalized, thanks to an array of molecularly targeted/endocrine therapies indicated for recurrent/advanced disease. New classes of targeted agents have been recently introduced or are in development for advanced breast cancer, including PARP inhibitors. The complexities of today's more personalized care pose multiple challenges to effective clinical and economic management of advanced breast cancer. It is for this reason that medical directors, oncologists, nurses and other healthcare professionals are provided with a detailed overview of current and emerging strategies for breast cancer, with a focus on individualized therapy. A review of the most recent clinical data for endocrine and molecularly targeted therapies will be provided, as will a discussion of new and emerging drug classes.

Upon completion of this activity, participants will be able to:

  • Quantify the clinical and economic burden of metastatic breast cancer, including factors that contribute to poor prognosis and increased costs

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer

  • Analyze efficacy and safety profiles of current and emerging PARP inhibitors for the treatment of metastatic breast cancer

  • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors

  • Assess strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies

  • Examine the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into current advanced breast cancer management paradigm


Faculty: Lee S. Schwartzberg, MD, FACP
Chief Medical Director
West Cancer Center and Research Institute
Professor of Medicine
University of Tennessee Health Science Center


Dr. Schwartzberg serves on an advisory board for Genomic Health. He serves as a consultant to Amgen, AstraZeneca, Bayer, BMS, Genentech, Helsinn, Myriad, Napo, Pfizer, and Spectrum. He has received grants/research support from Amgen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue